UM
The p38 MaPK inhibitor sB203580 abrogates Tumor necrosis Factor-induced Proliferative expansion of Mouse cD4(+)Foxp3(+) regulatory T cells
He, Tianzhen; Liu, Shuoyang; Chen, Shaokui; Ye, Jingyi; Wu, Xueqiang; Bian, Zhaoxiang; Chen, Xin
2018-07-09
Source PublicationFRONTIERS IN IMMUNOLOGY
ISSN1664-3224
Volume9
AbstractThere is now compelling evidence that tumor necrosis factor (TNF) preferentially activates and expands CD4(+)Foxp3(+) regulatory T cells (Tregs) through TNF receptor type II (TNFR2). However, it remains unclear which signaling transduction pathway(s) of TNFR2 is required for the stimulation of Tregs. Previously, it was shown that the interaction of TNF-TNFR2 resulted in the activation of a number of signaling pathways, including p38 MAPK, NF-kappa B, in T cells. We thus examined the role of p38 MAPK and NF-kappa B in TNF-mediated activation of Tregs, by using specific small molecule inhibitors. The results show that treatment with specific p38 MAPK inhibitor SB203580, rather than NF-kappa B inhibitors (Sulfasalazine and Bay 11-7082), abrogated TNF-induced expansion of Tregs in vitro. Furthermore, upregulation of TNFR2 and Foxp3 expression in Tregs by TNF was also markedly inhibited by SB203580. The proliferative expansion and the upregulation of TNFR2 expression on Tregs in LPS-treated mice were mediated by TNF-TNFR2 interaction, as shown by our previous study. The expansion of Tregs in LPS-treated mice were also markedly inhibited by in vivo treatment with SB203580. Taken together, our data clearly indicate that the activation of p38 MAPK is attributable to TNF/TNFR2-mediated activation and proliferative expansion of Tregs. Our results also suggest that targeting of p38 MAPK by pharmacological agent may represent a novel strategy to up-or downregulation of Treg activity for therapeutic purposes.
Keywordtumor necrosis factor TNF receptor type II p38 MAPK CD4(+)Foxp3(+) regulatory T cells proliferation
DOI10.3389/fimmu.2018.01556
URLView the original
Indexed BySCI
Language英语
WOS Research AreaImmunology
WOS SubjectImmunology
WOS IDWOS:000437880000001
PublisherFRONTIERS MEDIA SA
The Source to ArticleWOS
Fulltext Access
Citation statistics
Cited Times [WOS]:3   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionUniversity of Macau
Recommended Citation
GB/T 7714
He, Tianzhen,Liu, Shuoyang,Chen, Shaokui,et al. The p38 MaPK inhibitor sB203580 abrogates Tumor necrosis Factor-induced Proliferative expansion of Mouse cD4(+)Foxp3(+) regulatory T cells[J]. FRONTIERS IN IMMUNOLOGY,2018,9.
APA He, Tianzhen.,Liu, Shuoyang.,Chen, Shaokui.,Ye, Jingyi.,Wu, Xueqiang.,...&Chen, Xin.(2018).The p38 MaPK inhibitor sB203580 abrogates Tumor necrosis Factor-induced Proliferative expansion of Mouse cD4(+)Foxp3(+) regulatory T cells.FRONTIERS IN IMMUNOLOGY,9.
MLA He, Tianzhen,et al."The p38 MaPK inhibitor sB203580 abrogates Tumor necrosis Factor-induced Proliferative expansion of Mouse cD4(+)Foxp3(+) regulatory T cells".FRONTIERS IN IMMUNOLOGY 9(2018).
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[He, Tianzhen]'s Articles
[Liu, Shuoyang]'s Articles
[Chen, Shaokui]'s Articles
Baidu academic
Similar articles in Baidu academic
[He, Tianzhen]'s Articles
[Liu, Shuoyang]'s Articles
[Chen, Shaokui]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[He, Tianzhen]'s Articles
[Liu, Shuoyang]'s Articles
[Chen, Shaokui]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.